(Q37351659)

19 August 2017

1 reference

title

Is high HDL cholesterol always good? (English)

1 reference

19 August 2017

Anders G Olsson

1

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

19 August 2017

1 reference

19 August 2017

volume

41

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

11-18

1 reference

Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Antiinflammatory properties of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Time to rethink high-density lipoprotein?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Cholesteryl ester transfer protein: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Apolipoprotein A-I-containing lipoproteins, with or without apolipoprotein A-II, as progenitors of pre-beta high-density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Pros and cons of inhibiting cholesteryl ester transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Viability of developing CETP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

The paradox of dysfunctional high-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

Clinical Evaluation of Probucol in Hypercholesterolemia: Individual Lipoprotein Responses and Inhibitory Effect on Carotid Atherosclerosis Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802609534

10.1080/07853890802609534

21 January 2018

Identifiers

DOI

1 reference

release_c7gyiqioszb7lc2hwpitavnfnu

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/c7gyiqioszb7lc2hwpitavnfnu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference